


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31200147</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-5835</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>83</Volume>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Jun</Month>
                        <Day>04</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Leukemia research</Title>
                <ISOAbbreviation>Leuk. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Outcomes and second neoplasms in hairy cell leukemia: A retrospective cohort.</ArticleTitle>
            <Pagination>
                <MedlinePgn>106165</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0145-2126(19)30103-1</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.leukres.2019.06.001</ELocationID>
            <Abstract>
                <AbstractText>Hairy cell leukemia (HCL) is a rare chronic B-cell lymphoproliferative disease which is treated on the basis of small studies, making the literature still scarce of reports, especially of those conducted in Latin America. Here we intend to describe clinical characteristics, rates of response, survival and second neoplasms in HCL patients treated in a reference center in Brazil. All patients diagnosed with HCL between July/1987 and Jun/2018 were included in this analysis. Fifty-four patients were included in this analysis. Median age at diagnosis was 55 years (range, 26-88), with 37% being above 60 years-old. Most patients were treated with cladribine in our cohort (n = 36; 68%), administered through intravenous continuous infusion. Remaining patients were firstly managed with splenectomy (n = 7; 13%), IFN (n = 6; 11%) and rituximab (n = 2; 4%). In a univariate analysis, platelet count and B2M level at diagnosis were statistically associated with CR achievement (p = 0.004 and p = 0.024, respectively). A median follow-up time of 9 years was calculated. Estimated 10-year overall survival was 91.1% (95% confidence interval, 77-97). In this cohort, 10 patients had any second neoplasm, diagnosed before or after HCL. Regarding the sites of cancer, 69% were of skin - 8/16 carcinoma-type and 3/16 melanoma-type. Our response and survival data are similar to those reported by literature, which reaffirms the role of purine analogs in current HCL management. With a very long follow-up we also have observed a high incidence of second neoplasm.</AbstractText>
                <CopyrightInformation>Copyright © 2019 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>da Silva</LastName>
                    <ForeName>Wellington F</ForeName>
                    <Initials>WF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Cancer of São Paulo (ICESP), University of São Paulo, Av. Dr. Arnaldo, 251, Cerqueira César, São Paulo, SP, CEP 01246-000, Brazil. Electronic address: wellington.fernandes@hc.fm.usp.br.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Neto</LastName>
                    <ForeName>Abel Costa</ForeName>
                    <Initials>AC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Cancer of São Paulo (ICESP), University of São Paulo, Av. Dr. Arnaldo, 251, Cerqueira César, São Paulo, SP, CEP 01246-000, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>da Rosa</LastName>
                    <ForeName>Lidiane Inês</ForeName>
                    <Initials>LI</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Cancer of São Paulo (ICESP), University of São Paulo, Av. Dr. Arnaldo, 251, Cerqueira César, São Paulo, SP, CEP 01246-000, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Siqueira</LastName>
                    <ForeName>Isabela Assis</ForeName>
                    <Initials>IA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Cancer of São Paulo (ICESP), University of São Paulo, Av. Dr. Arnaldo, 251, Cerqueira César, São Paulo, SP, CEP 01246-000, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Amarante</LastName>
                    <ForeName>Guilherme Duffles</ForeName>
                    <Initials>GD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Cancer of São Paulo (ICESP), University of São Paulo, Av. Dr. Arnaldo, 251, Cerqueira César, São Paulo, SP, CEP 01246-000, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Velloso</LastName>
                    <ForeName>Elvira D R P</ForeName>
                    <Initials>EDRP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Cancer of São Paulo (ICESP), University of São Paulo, Av. Dr. Arnaldo, 251, Cerqueira César, São Paulo, SP, CEP 01246-000, Brazil; Hospital das Clinicas, University of São Paulo, Av. Dr. Enéas de Carvalho Aguiar, 155, São Paulo, SP, CEP 05403-000, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rego</LastName>
                    <ForeName>Eduardo Magalhães</ForeName>
                    <Initials>EM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Cancer of São Paulo (ICESP), University of São Paulo, Av. Dr. Arnaldo, 251, Cerqueira César, São Paulo, SP, CEP 01246-000, Brazil; Hospital das Clinicas, University of São Paulo, Av. Dr. Enéas de Carvalho Aguiar, 155, São Paulo, SP, CEP 05403-000, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rocha</LastName>
                    <ForeName>Vanderson</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Cancer of São Paulo (ICESP), University of São Paulo, Av. Dr. Arnaldo, 251, Cerqueira César, São Paulo, SP, CEP 01246-000, Brazil; Hospital das Clinicas, University of São Paulo, Av. Dr. Enéas de Carvalho Aguiar, 155, São Paulo, SP, CEP 05403-000, Brazil; Churchil Hospital, Oxford University Hospital, NHSBT, Oxford, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Buccheri</LastName>
                    <ForeName>Valeria</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Cancer of São Paulo (ICESP), University of São Paulo, Av. Dr. Arnaldo, 251, Cerqueira César, São Paulo, SP, CEP 01246-000, Brazil; Hospital das Clinicas, University of São Paulo, Av. Dr. Enéas de Carvalho Aguiar, 155, São Paulo, SP, CEP 05403-000, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>04</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Leuk Res</MedlineTA>
            <NlmUniqueID>7706787</NlmUniqueID>
            <ISSNLinking>0145-2126</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Beta 2-microglobulin</Keyword>
            <Keyword MajorTopicYN="N">Cladribine</Keyword>
            <Keyword MajorTopicYN="N">Hairy cell leukemia</Keyword>
            <Keyword MajorTopicYN="N">Second primary neoplasm</Keyword>
            <Keyword MajorTopicYN="N">Survival</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>04</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31200147</ArticleId>
            <ArticleId IdType="pii">S0145-2126(19)30103-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.leukres.2019.06.001</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

